Physician profile
Sean Nonnemaker
NPI 1245573609
$2,506.48
in general payments reported to CMS, 2019-2025
32 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $43.82 · 2021: $533 · 2022: $566 · 2023: $606 · 2024: $277 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $271.29 | 2019-2023 | Xarelto |
| Abbvie INC. | $258.98 | 2021-2023 | |
| Pfizer INC. | $245.18 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $226.04 | 2022-2024 | Austedo Xr, Austedo |
| Novo Nordisk INC | $169.41 | 2019-2022 | |
| Lilly USA, LLC | $163.39 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $130.03 | 2021-2025 | |
| Inari Medical, INC. | $125.30 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $109.37 | 2025 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.09 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $76.18 | 2022-2024 | Rexulti |
| Abiomed | $60.42 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $56.77 | 2019-2022 | |
| Gilead Sciences, INC. | $56.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.09 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $41.98 | 2021-2023 | Watchman Access System |
| Biogen, INC. | $39.51 | 2021 | |
| Eisai INC. | $38.52 | 2021-2022 | |
| Exact Sciences Corporation | $32.25 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $30.32 | 2022 | |
| Ucb, INC. | $28.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $28.55 | 2024 | |
| Amarin Pharma, INC. | $23.96 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.62 | 2023 | Crysvita |
| Astellas Pharma US INC | $21.68 | 2019 | |
| Mannkind Corporation | $19.01 | 2022 | |
| Amgen INC. | $17.83 | 2025 | Repatha, Otezla |
| Tactile Systems Technology INC | $17.54 | 2024 | Entre Plus, Flexitouch Plus |
| Nestle Healthcare Nutrition INC. | $16.82 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2025 | Xifaxan |
| Stryker Corporation | $14.84 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Nonnemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.